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Abstract
Background: In older patients with aortic stenosis (AS) undergoing TAVI, the potential role of prior CGA is not well
established. To explore the value of comprehensive geriatric assessment (CGA) for predicting mortality and/or
hospitalisation within the first 3 months after transcatheter aortic valve implantation (TAVI).
Methods: An international, multi-centre, prospective registry (CGA-TAVI) was established to gather data on CGA
results and medium-term outcomes in geriatric patients undergoing TAVI. Logistic regression was used to evaluate
the predictive value of a multidimensional prognostic index (MPI); a short physical performance battery (SPPB); and
the Silver Code, which was based on administrative data, for predicting death and/or hospitalisation in the first
3 months after TAVI (primary endpoint).
Results: A total of 71 TAVI patients (mean age 85.4 years; mean log EuroSCORE I 22.5%) were enrolled. Device success
according to VARC criteria was 100%. After adjustment for selected baseline characteristics, a higher (poorer) MPI score
(OR: 3.34; 95% CI: 1.39–8.02; p = 0.0068) and a lower (poorer) SPPB score (OR: 1.15; 95% CI: 1.01–1.54; p = 0.0380) were
found to be associated with an increased likelihood of the primary endpoint. The Silver Code did not show any
predictive ability in this population.
Conclusions: Several aspects of the CGA have shown promise for being of use to physicians when predicting TAVI
outcomes. While the MPI may be useful in clinical practice, the SPPB may be of particular value, being simple and quick
to perform. Validation of these findings in a larger sample is warranted.
Trial registration: The trial was registered in ClinicalTrials.gov on November 7, 2013 (NCT01991444).
Keywords: Transcatheter aortic valve implantation (TAVI), Comprehensive geriatric assessment (CGA), Multidimensional
prognostic index (MPI), Short physical performance battery (SPPB), Silver code
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Background
Severe symptomatic stenosis of the aortic valve (aortic
stenosis; AS) is associated with mortality of up to 50% at
1 year if left untreated [1, 2]. The outcome of surgical
aortic valve replacement (SAVR) is generally predicted
with the aid of quantitative scales such as the
EuroSCORE or the Society of Thoracic Surgeons (STS)
risk score. However, the accuracy of such algorithms for
assessing older-age, multi-morbid patients undergoing
transcatheter aortic valve implantation (TAVI) is low
[3–5]. This is mainly due to the absence of variables
related to ageing, such as frailty, mental status, social
support, and overall health. There is evidence that
additionally evaluating these factors can help provide a
more precise estimation of an older person’s response to
treatment [3, 6, 7]. Indeed, a recent report from the
American College of Cardiology (ACC) advocates assess-
ment of frailty and cognitive function prior to determining
a patient’s suitability for TAVI [8]. The inclusion of a
geriatrician in the Heart Team responsible for assessing
patients prior to TAVI may therefore be warranted [9].
A comprehensive geriatric assessment (CGA) is a
multidimensional diagnostic process for evaluating an
individual’s clinical, psychosocial, and functional charac-
teristics [10, 11]. It usually consists of functional tests
complementing usual clinical evaluation. For example,
CGA may include the calculation of a multidimensional
prognostic index (MPI) based on mental and nutritional
status, number of co-morbid conditions and medica-
tions, living arrangements, and the ability to cope with
activities of daily living [12, 13]. Pilotto et al. showed
that the MPI had high predictive power for assessing
mortality after hospitalisation of older patients [13]. For
TAVI specifically, few studies have evaluated CGA and
its components for outcome prediction [3, 14–16]. For
example, Stortecky et al. evaluated a geriatric assessment
that contained many of the same components as the
MPI, and found that many of the included items were
predictive of mortality and the occurrence of a major ad-
verse cardiac or cerebrovascular event (MACCE) at
30 days and 1 year after the procedure [14]. All previous
studies originated from single-centre experiences.
We aimed to determine the power of CGA for predict-
ing the combined endpoint of mortality and stroke
within the 3 months subsequent to TAVI based on data
from a multi-centre, prospective cohort. We further
characterised changes in CGA over time, and provide
additional evidence for the utility of TAVI in a geriatric,
comorbid population.
Methods
Patients and registry design
The CGA-TAVI registry is a prospective, inter-
national, multi-centre, observational registry [17].
Patients were enrolled at three centres in Italy
(Careggi Hospital, Florence), the Netherlands
(Academic Medical Center, Amsterdam) and Canada
(Centre Hospitalier de l’Université de Montréal) be-
tween August 2013 and December 2015. Individuals
were eligible if they were aged >80 years, had symp-
tomatic severe calcific aortic valve (AV) stenosis, and
were assigned to undergo transaortic, transapical or
transfemoral TAVI. Patients were excluded if TAVI
was being performed as an emergency procedure or
if patients were unable to participate in the follow-
up. Overall, 603 patients underwent TAVI at one of
the three study centres during the study period
(Italy: 68, Canada: 95; the Netherlands: 440. Of
these, 71 patients were enrolled in the CGA-TAVI
registry: 41, 15 and 15 from the sites in Italy,
Canada and the Netherlands, respectively.
Baseline assessment
A detailed description of the information docu-
mented has been previously published [17]. Briefly,
data regarding demographics, comorbidities, and
prior cardiovascular interventions were collected at
hospital admission. A CGA was performed by a
geriatrician for each patient. This included calcula-
tion of the MPI [12, 13], which consisted of the
following components: Activities of Daily Living
(ADL; 6 items) [18, 19]; Instrumental Activities of
Daily Living (IADL; 8 items) [20]; Short Portable
Mental Status Questionnaire (SPMSQ; 10 items)
[21]; Cumulative Illness Rating Scale (CIRS; 14
items) [22, 23]; Mini Nutritional Assessment (MNA;
18 items) [24]; Exton-Smith Scale (ESS; 5 items)
[25]; number of drugs used (1 item); and co-
habitation status (1 item). In each case, a tripartite
hierarchy was used for scoring (no problems: 0
points; minor problems: 0.5 points; severe problems:
1 point). The boundaries for these scores were based
on the cut-off points derived from the associated lit-
erature [12]. A Silver Code value was also calculated
from administrative data for further prognostic
stratification [26] and a Short Physical Performance
Battery (SPPB) was performed, which involved re-
peated chair stands, balance testing, and an 8-ft
(2.44 m) walk [27]. Detailed breakdowns of the three
assessment scores can be found in Appendices 1, 2
(MPI), 3 (Silver Code) and 4 (SPPB). Procedural
characteristics were also documented.
Follow-up assessment and outcomes
Patients were scheduled for follow-up at discharge,
30 days and 3 months post-procedure. These visits
were conducted at the patient’s enrolling centre and
involved repetition of the CGA performed at the
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baseline assessment. Death, all-cause hospitalisation,
TAVI-related hospitalisation, stroke, transient ischae-
mic attack (TIA), myocardial infarction (MI), life-
threatening bleeding, acute kidney injury, coronary
artery obstruction requiring intervention, major
vascular complications, valve dysfunction requiring
repeat procedure, or worsening congestive heart fail-
ure (CHF) were recorded, as defined in the Valve
Academic Research Consortium-2 (VARC-2) consen-
sus document [28].
Endpoints
The primary endpoint was death and/or hospitalisation
within the first 3 months after TAVI. The secondary
endpoint was death and/or non-fatal stroke within the
same period. Changes in the scores of the components
of the CGA from baseline to 3 months were also
evaluated.
Data management and statistics
Data were entered into an online database via the com-
pletion of an electronic case report form (eCRF; s4trials,
Berlin, Germany). Details were automatically checked
for plausibility and completeness.
Data were analysed using descriptive statistics, with
categorical variables presented as absolute values and
percentages and continuous variables as means with
standard deviations (SD). A logistic regression was
used to evaluate the predictive value of CGA compo-
nents (MPI, SPBB and Silver Code) for the primary/
secondary endpoints. Age, gender, New York Heart
Association (NYHA) class and surgical risk (Euro-
SCORE/STS) were used as co-variables. Logistic re-
gression results are presented as odds ratios (OR)
with 95% Wald confidence limits (95% CI) and p-
values. CGA changes from baseline to 3-month
follow-up were tested for significance using a t-test.
P-values of <0.05 were considered significant.
Data were analysed using IBM SPSS statistics version
24 (IBM corporation, Amonk, New York, USA).
Results
Baseline patient characteristics
Overall, 44 patients (62%) were female. Means for age
and body mass index (BMI) were 85.4 ± 2.9 years and
24.7 ± 3.7 kg/m2, respectively (Table 1). The most preva-
lent comorbidity was hypertension (83.1%), followed by
coronary artery disease (53.5%), peripheral artery disease
(28.2%), diabetes mellitus (26.8%), prior MI (23.9%), and
pulmonary disease (15.5%). In terms of surgical risk, the
mean log EuroSCORE and STS scores were 22.5 ± 13.2%
and 5.8 ± 3.9%, respectively.
Table 1 Patient characteristics
Mean ± SD (n) / n/N (%)
Age [years] 85.4 ± 2.9 (n = 71)
Gender [female] 44/71 (62.0)
BMI [kg/m2] 24.7 ± 3.7 (n = 71)
Comorbidities
Hypertension 59/71 (83.1)
Diabetes mellitus 19/71 (26.8)
PAD 20/71 (28.2)
Prior stroke/TIA 6/71 (8.5)
CAD 38/71 (53.5)
Prior MI 17/71 (23.9)
Pulmonary diseasea 11/71 (15.5)
Pulmonary hypertension 35/71 (49.3)
Creatinine ≥2.0 mg/dlb 5/71 (7.0)
Dialysis 2/71 (2.8)
Prior cardiovascular intervention
PCI 16/71 (22.5)
CABG 13/71 (18.3)
Mitral valve replacement 2/71 (2.8)
Tricuspid valve replacement 0/71 (0)
Balloon aortic valvuloplasty 6/71 (8.5)
PPI 5/71 (7.0)
Surgical risk
Log EuroSCORE I 22.5 ± 13.2 (n = 71)
STS risk score 5.8 ± 3.9 (n = 71)
AS-related symptoms (%)
Syncope 5/71 (7.0)
Dizziness with exertion 5/71 (7.0)
CCS angina grade
Class III 7/70 (10.0)
Class IV 0/70 (0)
NYHA classification
Class III 50/71 (70.4)
Class IV 7/71 (9.9)
AS echocardiographic parameters
AV peak gradient (mmHg) 78.5 ± 17.8 (n = 59)
AV mean gradient (mmHg) 50.5 ± 14.1 (n = 61)
Vmax (m/s) 4.2 ± 0.9 (n = 24)
Effective orifice area (cm2) 0.9 ± 0.6 (n = 37)
LVEF (%) 50.9 ± 12.0 (n = 62)
Legend: BMI body mass index, PAD peripheral artery disease, TIA transient
ischaemic attack, CAD coronary artery disease, MI myocardial infarction,
PCI percutaneous coronary intervention, CABG coronary artery bypass
grafting, PPI permanent pacemaker implantation, log Euro SCORE logistic
European System for Cardiac Operative Risk Evaluation, STS Society of
Thoracic Surgeons, AS aortic stenosis, LVEF left ventricular ejection fraction,
AV aortic valve, CCS Canadian Cardiovascular Society, NYHA New York
Heart Association, Vmax maximum velocity
aDefined as chronic obstructive pulmonary disease, asthma, a forced
expiratory volume-1 of < 1.0, or oxygen dependency
bExcluding patients with dialysis
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The majority of patients were at NYHA class III
(70.4%) or IV (9.9%). Further AS-related symptoms
were class III angina (10.0%), dizziness with exertion
(7.0%), and syncope (7.0%). Regarding echocardiog-
raphy, peak and mean AV gradients were 78.5 ± 17.8
and 50.5 ± 14.1 mmHg, respectively, with a left ven-
tricular ejection fraction (LVEF) of 50.9 ± 12.0%, a
mean Vmax of 4.2 ± 0.9 m/s, and an effective orifice
area of 0.9 ± 0.6 cm2.
Procedural characteristics and periprocedural outcomes
Details about procedural aspects are provided in the
supplementary data (Appendix 5). Devices were
placed successfully (as defined by VARC-2 [28]) in
all patients (Appendix 6). The rate of intraoperative
complications was 17.1%, which were vascular com-
plications requiring treatment in 10.0% of patients
and access-related in 5.6%. No conversion to open
surgery was necessary. Paravalvular regurgitation was
moderate in 2.9%, with no severe regurgitation. Post-
procedural AV peak and mean gradients were 20.0 ±
12.4 and 11.3 ± 7.2 mmHg, respectively.
Outcomes at 3-months
In total, 6 patients died (8.5%) and 9 were hospita-
lised (13.8%) by the 3-month follow-up. The primary
endpoint (death and/or hospitalisation in the first
3 months) was observed in 13/71 patients (18.3%)
(Table 2). After adjustment for baseline characteris-
tics, a higher (poorer) MPI score (OR: 3.34; 95% CI:
1.39–8.02; p = 0.0068) and a lower (poorer) SPPB
score (OR: 1.15; 95% CI: 1.01–1.54; p = 0.0380) were
found to be associated with an increased odds of
primary endpoint achievement (Table 3).
The secondary endpoint (death and/or non-fatal
stroke in the first 3 months) was observed in 6
patients (8.5%) (Table 2). After multivariate adjust-
ment, a higher (poorer) MPI score (OR: 4.75; 95% CI:
1.40–16.08; p = 0.0123) and a lower (poorer) SPPB
score (OR: 1.62; 95% CI: 1.08–2.43; p = 0.0188) were
associated with a greater odds of secondary endpoint
achievement (Table 3).
CGA change from baseline to 3 months
Between baseline and 3 months, the total MPI score
decreased only slightly, from a mean of 0.34 ± 0.11
to 0.30 ± 0.13 (mean intra-individual change: −0.02 ±
0.12; p = 0.25) (Appendix 7). However, the CIRS and
ESS components changed by a statistically significant
amount (−0.12 ± 0.25; p < 0.001 and −0.04 ± 0.13;
p = 0.04, respectively). While the change in Silver
Code was small, the SPPB score increased signifi-
cantly (+1.86 ± 2.76; p < 0.001).
Discussion
Of the multiple components of the CGA that were
evaluated, the MPI and the SPPB both had value for
predicting the likelihood of death and/or hospitalisa-
tion in the first 3 months following TAVI. In terms
of time-efficiency, the SPPB appears to be the
favourable approach, with the MPI perhaps not
adding sufficient additional predictive value to war-
rant such a time-consuming assessment.
Outcomes
In our patients, the rate of all-cause mortality at
30 days (2.8%) was within the range (1.1%–5.9%) re-
ported by large-scale studies in patients with a simi-
lar level of surgical risk and mean ages above
80 years, such as the PARTNER II trial and
SOURCE 3, WIN-TAVI, Swiss TAVI, and PRAG-
MATIC registries [29–33]. Though a less commonly
reported outcome, the same was true of the rate of
rehospitalisation (7.2% vs. 4.6% in the PARTNER II
SAPIEN 3 trial and 6.5% in the overall PARTNER II
trial) [29, 34]. Variations in rates between studies are
likely due to differing patient characteristics, access
routes, and the valves/delivery devices available
during study periods. Our findings regarding three-
month outcomes could not be easily compared to
previous studies, as this time-point is not largely
reported upon in the literature.
Table 2 Short- and medium-term outcomes
≤30 daysa
n/N (%)
≤3 months
n/N (%)
Primary endpoint
(Death and/or hospitalisation)
5/70 (7.1) 13/71 (18.3)
Secondary endpoint
(Death and/or non-fatal stroke)
2/71 (2.8) 6/71 (8.5)
All-cause mortality 2/71 (2.8) 6/71 (8.5)
Non-fatal complications (n = 69) (n = 65)
All-cause hospitalisation 5/69 (7.2) 9/65 (13.8)
Valve-related hospitalisation 3/69 (4.3) 2/65 (6.2)
Non-fatal stroke 0/69 (0.0) 0/62 (0.0)
Acute kidney injury (stage 2 or 3) 3/69 (4.3) 5/64 (7.8)
Major vascular complication 1/69 (1.4) 0/64 (3.1)
Repeat procedure for valve dysfunction 0/69 (0) 1/62 (1.6)
Myocardial infarction 0/69 (0) 0/62 (0)
PPI 9/69 (13.0) 9/65 (13.8)
Legend: CHF congestive heart failure, MI myocardial infarction, NYHA New York
Heart Association, CCS Canadian Cardiovascular Society, PPI permanent
pacemaker implantation
a≤ 30 days includes all complications which occurred periprocedurally, during
the phase of hospitalisation for TAVI and after discharge within 30 days
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Surgical risk scores
EuroSCORE and STS algorithms are conventional
tools for assessing cardiac operative risk. It has been
suggested that the latter is slightly more accurate in
TAVI patients [4, 5], though neither are ideal. Pa-
tients in the present study had expected mortality
rates of 22.5% (EuroSCORE I) and 5.8% (STS), and
though the latter was closer to the observed rate,
both were excessively elevated. Even the more up-to-
date EuroSCORE II has been shown to have subopti-
mal discriminatory power, suggesting the need for
alternative or additional assessment tools [35, 36].
Multidimensional prognostic index
Use of a CGA during clinical assessment of operative
risk in AS patients has been suggested as a way to
address the shortcomings of the EuroSCORE and STS
score, and better predict outcomes [17, 36]. In the
present study, both MPI and SPPB were found to
have predictive value for determining the likelihood
of short-term mortality/hospitalisation or stroke after
TAVI. Interestingly, while high MPI was a “negative
predictor” in the univariate analysis, it became a
“positive predictor” after adjusting for age, gender,
NYHA class and surgical risk. This change of direc-
tion can be explained by the clinical setting; younger
patients with a low MPI are typically treated with
SAVR, while elderly patients with a high MPI are un-
likely to be treated at all. Consequently, our TAVI
population was likely composed of patients with a
lower age and high MPI or a higher age and low
MPI, resulting in a switch of the direction of the
odds ratio at multivariate analysis. This reflection of
the clinical context is supportive of the “real” associ-
ation between MPI score and outcomes.
Though no other studies appear to have specific-
ally reported on the predictive value of MPI in
TAVI, several have shown higher MPI scores to be
significantly associated with greater rates of mortality
in older patients with a variety of acute illnesses, in-
cluding heart failure and TIA [12, 13, 37–40]. Other
studies have evaluated other multi-component
models for predicting mortality and morbidity after
cardiac surgery [41]. For TAVI specifically, Green et
al. found that patients with a high frailty score, as
determined by gait speed, grip strength, serum
albumin and ADL, were at greater risk of one-year
mortality [15]. The five-component frailty score pro-
posed by Kamga et al. was found to predict one-year
mortality after transfemoral TAVI [16]. Stortecky et
al. identified numerous parameters in their Multidi-
mensional Geriatric Assessment that were predictive
of 30-day and one-year mortality and MACCE after
TAVI [14]. Data from the PARTNER trial were used
to construct models for predicting a poor outcome,
defined as death or a low/significantly decreased
quality of life, after TAVI [42]. These models were
subsequently validated in a large multi-centre cohort
of TAVI patients, with an incremental increase in
discriminative ability identified on the addition of
markers of frailty and disability [43]. In agreement
with the data from our CGA registry, these studies
demonstrate the potential value of such multi-
component analyses for predicting outcome after
TAVI.
Short physical performance battery
A significant drawback of these multidimensional
evaluation tools, however, is that they are extremely
time-consuming. In the present work, we found that
use of the SPPB alone was equally as effective as the
MPI for predicting death and/or hospitalisation, and
death and/or non-fatal stroke, in the first 3 months
after TAVI. This short series of tests is
Table 3 Logistic regression for the prediction of events at 3 months by CGA at baseline
Univariable OR (95% CI) p-value Multivariable OR (95% CI) p-value
Death and/or hospitalisation
Increasing MPI score (high vs. low) 0.66 (0.54–0.81) < 0.0001 3.34 (1.39–8.02)a 0.0068
Decreasing SPPB (low vs. high) 1.35 (1.19–1.53) < 0.0001 1.15 (1.01–1.54) 0.0380
Increasing Silver Code (high vs. low) 0.94 (0.92–0.97) < 0.0001 1.03 (0.91–1.15) 0.6576
Death and/or non-fatal stroke
Increasing MPI score (high vs. low) 0.49 (0.36–0.63) < 0.0001 4.75 (1.40–16.08) 0.0123
Decreasing SPPB (low vs. high) 1.89 (1.36–2.64) 0.0002 1.62 (1.08–2.43) 0.0188
Increasing Silver Code (high vs. low) 0.90 (0.87–0.94) < 0.0001 1.04 (0.87–1.23) 0.6938
Legend: MPImultidimensional prognostic index, SPPB short physical performance battery. All values adjusted for age, gender, NYHA class and surgical risk (EuroSCORE)
aThe direction of the OR changed with the introduction of age into the model
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recommended by the European Union Geriatric
Medicine Society (EUGMS) as part of a CGA in
older AS patients [17], although it appears that there
is little published evidence in support of using it for
assessing TAVI candidates specifically. The concept
of tests of physical ability to predict outcome after
cardiac surgery has been evaluated in other studies.
Afilalo et al. demonstrated that a slow 5-m gait
speed was associated with a greater risk of operative
mortality and in-hospital mortality and major
morbidity in older patients undergoing cardiac
surgery [7, 44]. They further determined that use of
this parameter alone was superior to a variety of
other frailty scales [6]. In patients undergoing TAVI
specifically, 5-m gait speed has been shown to be in-
dependently associated with 30-day mortality after
adjustment for STS score and other relevant baseline
characteristics [45]. Stortecky et al. reported that the
“timed get-up and go” (TUG) test had the greatest
predictive ability of all of the individual geriatric
assessment tools that they investigated [14]. In
combination with either the STS or EuroSCORE, the
TUG was superior to the other components evalu-
ated for predicting all-cause mortality and MACCE
during the first year after TAVI. A recent report by
the ACC recommends that a 5-m gait speed test and
a 6 min walk test be used to assess frailty and phys-
ical functioning, respectively, when determining a
patient’s suitability for TAVI [8].
The simplicity of physical tests such as the SPPB
is not their only advantage, with the lack of subjec-
tivity on the part of both physician and patient
providing a level of accuracy that cannot be obtained
using questionnaire-based assessment. This is
particularly relevant for the advanced-age TAVI
population, where cognitive impairment is a poten-
tially significant confounding factor when evaluating
self-reported parameters [6].
Silver code
According to our data, the Silver Code had no value
for predicting death/hospitalisation or death/stroke
during the first 3 months after TAVI. The calculation
of this parameter prior to deciding on the suitability
of a patient for TAVI is another recommendation of
the EUGMS [17]. Previous studies have demonstrated
a relationship between Silver Code and one-year mor-
tality, although this was in the setting of the Emer-
gency Department [26, 46]. As the Silver Code is
determined from administrative data, it is particularly
suited to planned procedures such as TAVI. There-
fore, although it was not found to be an independent
predictor of outcome in the present analysis, it should
perhaps not be discounted. Further evaluation in a
larger population may clarify its utility as part of a
CGA prior to TAVI.
Limitations
Firstly, as an observational study, inherent limita-
tions such as a higher potential for missing data are
present. However, the observational aspect carried
several advantages, such as an evaluation of TAVI
patients in a real-world setting, avoiding the con-
founding issue of the strict inclusion and exclusion
criteria used for clinical trials. This is particularly
important, as geriatric patients are often those ex-
cluded due to high levels of comorbidity. Secondly,
our findings are currently only applicable to geriatric
patients at higher surgical risk. Considering that
there is a current shift in clinical practice towards
TAVI in lower-risk patients who are normally eligible
for surgical heart valve replacement, re-evaluation of
CGA in different populations may become necessary.
In addition, we were only able to obtain data for a
modest number of patients from three participating
sites, limiting statistical power and generalisability.
Indeed, the relatively low incidence of mortality and
stroke at 3 months in a fairly small sample may have
resulted in suboptimal power to detect baseline
characteristics that are predictive for this outcome.
Future studies in larger samples would be useful for
clarification.
Conclusion
Several aspects of the CGA have shown promise for
being of use to physicians when predicting the likeli-
hood of death, rehospitalisation and non-fatal stroke
following TAVI. The strong association between MPI
and such outcomes indicates its potential utility in
clinical practice. In addition, the SPPB may have sig-
nificant value, being simple and quick to perform;
however, the modest sample size included herein
limit the formation of firm conclusions, and valid-
ation of these findings in a larger sample of TAVI
patients with a greater range of surgical risk is
warranted.
Clinical perspectives
The accuracy of conventional surgical risk scores is
known to be suboptimal for predicting the outcomes of
TAVI in elderly aortic stenosis patients. This study
shows a potential benefit of adding items from a com-
prehensive geriatric assessment (CGA) to pre-
intervention assessments. This now requires further val-
idation in larger cohorts.
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Appendix 1
Provides an overview about the Multidimensional Prog-
nostic Index (MPI).
Appendix 2
Provides a breakdown of the Multidimensional Prognostic
Index (MPI).
Table 4 Calculation of the Multidimensional Prognostic Index (MPI)
Problem severity
No (= 0 points) Minor (= 0.5 points) Severe (= 1 point)
1. Co-habitation status Living with relatives/nurse Living in an institution Living alone
2. Current medication use 0–3 medications 4–6 medications ≥7 medications
3. ADL score 6–5 4–3 2–0
4- IADL score 8–6 5–4 3–0
5. SPMSQ score 0–3 4–7 8–10
6. ESS score 16–20 10–15 5–9
7. CIRS CI 0 1–2 ≥3
8. MNA score ≥24 17–23.5 <17
Total MPI score (sum of points/8):
Low-risk: ≤0.33
Moderate-risk: 0.34–0.66
High-risk: >0.66
Legend: ADL activities of daily living, IADL instrumental ADL, SPMSQ short portable mental status questionnaire, ESS Exton-Smith scale, CIRS cumulative illness
raiting scale, CI comorbidity index, MNA mini nutritional assessment, MPI multidimensional prognostic index. The numbering on the left-hand side of factors
corresponds to the numbering in Appendix 2
Table 5 Breakdown of MPI Scoring
3. Activities of Daily Living (ADL) Points
Bathing (sponge bath, tub bath, or shower)
Receives no assistance (gets in and out of the tub by self if tub is usual means of bathing) 1
Receives no assistance in bathing only one part of the body (such as back or leg) 1
Receives assistance in bathing more than one part of the body (or not bathed) 0
Dressing (gets clothes from closets and drawers, including underclothes/outer garments and using fasteners/
braces, if worn)
Gets clothes and gets completely dressed without assistance 1
Gets clothes and gets dressed without assistance except for assistance in tying shoes 1
Receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed 0
Toileting
Goes to “toilet room” cleans self, and arranges clothes without assistance (may use object for
support such as cane, walker, or wheelchair and may manage night bedpan or commode,
emptying same in morning)
1
Receives assistance in going to “toilet room” or in cleaning self or in arranging clothes after
elimination or in use of night bedpan or commode
0
Doesn’t go to room termed “toilet” for the elimination process 0
Transfer
Moves in and out of bed as well as in and out of chair without assistance (may be using object for
support such as cane or walker)
1
Moves in and out of bed or chair with assistance 0
Doesn’t get out of bed 0
Continence
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Table 5 Breakdown of MPI Scoring (Continued)
Controls urination and bowel movement completely by self 1
Has occasional “accidents” 0
Supervision helps keep urine or bowel control, catheter is used, or is incontinent 0
Feeding
Feeds self without assistance 1
Feeds self except for getting assistance in cutting meat or buttering bread 1
Receives assistance in feeding or is fed partly or completely by using tubes or intravenous fluids 0
Max ADL score (best performance): 6
4. Instrumental Activities of Daily Living Scale (IADL)
Ability to use telephone
Operates telephone on own initiative: Iooks up and dials numbers, etc. 1
Dials a few well-known numbers 1
Answers telephone but does not dial 1
Does not use telephone at all 0
Shopping
Takes care of all shopping needs independently 1
Shops independently for small purchases 0
Needs to be accompanied on any shopping trip 0
Completely unable to shop 0
Food preparation
Plans, prepares and serves adequate meals independently 1
Prepares adequate meals if supplied with ingredients 1
Heats, serves and prepares meals or prepares meals but does not maintain adequate diet 0
Needs to have meals prepared and served 0
Housekeeping
Maintains house alone or with occasional assistance (e.g. “heavy work domestic help”) 1
Performs light daily tasks such as dishwashing, bed-making 1
Performs light daily tasks but cannot maintain acceptable level of cleanliness 1
Needs help with all home maintenance tasks 0
Does not participate in any housekeeping tasks 0
Laundry
Does personal laundry completely 1
Launders small items; rinses stockings, etc. 1
All laundry must be done by others 0
Mode of transportation
Travels independently on public transportation or drives own car 1
Arranges own travel via taxi, but does not otherwise use public transportation 1
Travels on public transportation when accompanied by another 1
Travel limited to taxi or automobile with assistance of another 0
Does not travel at all 0
Responsibility for own medications
Is responsible for taking medication in correct dosages at correct time 1
Takes responsibility if medication is prepared in advance in separate dosage 0
Is not capable of dispensing own medication 0
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Table 5 Breakdown of MPI Scoring (Continued)
Ability to handle finances
Manages financial matters independently (budgets, writes checks, pays rent, bills, goes to bank),
collects and keeps track of income
1
Manages day-to-day purchases, but needs help with banking, major purchases, etc 1
Incapable if handling money 0
Max IADL score (best performance): 8
5. Short Portable Mental Status Questionnaire (SPMSQ)
What is the date today? (Correct only when the month, date, and year are all correct) If incorrect: 1
What day of the week is it? If incorrect: 1
What is the name of this place? (Correct if any of the description of the location is given) If incorrect: 1
What is your street address? If incorrect: 1
How old are you? If incorrect: 1
When were you born? If incorrect: 1
Who is the president (or the Pope) now? (Requires only the correct last name) If incorrect: 1
Who was president (or the Pope) just before him? If incorrect: 1
What was your mother’s maiden name? If incorrect: 1
Subtract 3 from 20 and keep subtracting 3 from each new number at least for 3 times (the entire
series must be performed correctly to be scored as correct)
If incorrect: 1
Max SPMQ score (worst performance): 10
6. Exton-Smith Scale (ESS)
General Condition
Bad 1
Poor 2
Fair 3
Good 4
Mental State
Stuporous 1
Confused 2
Apathetic 3
Alert 4
Activity
In bed all day 1
Chairfast 2
Walks with help 3
Ambulant 4
Incontinence
Doubly incontinent 1
Usually of urine 2
Occasional 3
None 4
Mobility in Bed
Immobile 1
Very limited 2
Slightly limited 3
Full 4
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Table 5 Breakdown of MPI Scoring (Continued)
Max ESS score (best performance): 20
7. Cumulative Illness Rating Scale
Point allocation based on disease severity
None Mild Moderate Severe Extremely
severe
Cardiac (heart only) 1 2 3 4 5
Hypertension (rating is based on severity) 1 2 3 4 5
Vascular (arteries, veins, lymphatics) 1 2 3 4 5
Respiratory (lungs, bronchi, trachea) 1 2 3 4 5
EENT (eye, ear, nose, throat, Iarynx) 1 2 3 4 5
Upper GI (esophagus, stomach, duodenum, biliary and pancreatic trees) 1 2 3 4 5
Lower GI (intestines, hernias) 1 2 3 4 5
Hepatic (liver only) 1 2 3 4 5
Renal (kidneys only) 1 2 3 4 5
Other GU (urethers, bladder, urethra, prostate, genitals) 1 2 3 4 5
Musculo-skeletal-integumentary (muscles, bone, skin) 1 2 3 4 5
Neurological (brain, spinal cord, nerves) 1 2 3 4 5
Endocrine-metabolic (including diabetes, hyperlipidemia, infections, toxicity) 1 2 3 4 5
Psychiatric (dementia, depression, anxiety, agitation, psychosis) 1 2 3 4 5
Max comorbidity index (number of items with a score of ≥3; excluding the psychiatric item; most severe): 13
8. Mini Nutritional Assessment (MNA) Points
Anthropometric Assessment
Body Mass Index
< 19 0
19–20 1
21–22 2
≥ 23 3
Mid-arm circumference (cm)
< 21 0
22 0.5
> 22 1
Calf circumference (cm)
< 31 0
> 31 1
Weight loss (last 3 months)
Loss of >3 kg 0
Do not know 1
Loss between 1 and 3 kg 2
No weight loss 3
General Assessment
Lives independently (not in a nursing home or hospital)
No 0
Yes 1
Takes more than 3 prescription drugs per day
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Table 5 Breakdown of MPI Scoring (Continued)
Yes 0
No 1
Has suffered psychological stress or acute disease in the past 3 months
Yes 0
No 1
Mobility
Bed/chair-bound 0
Able to get out of bed / chair but does not go out 1
Goes out 2
Neuropsychological problems
Severe dementia/depression 0
Mild dementia 1
Psychological problems 2
Pressure sores or skin ulcers
Yes 0
No 1
Dietary Assessment
How many full meals does the patient eat daily?
1 meal 0
2 meals 1
3 meals 2
Consumes at least 1 serving of dairy products (milk, cheese, yogurt) per day
No 1
Yes 0
Consumes 2 or more servings of Legumes or eggs per week
No 0
Yes 0.5
Consumes meat, fish or poultry every day
No 0
Yes 1
Consumes 2 or more servings of fruits or vegetables per day?
No 0
Yes 1
Has food intake declined over the past 3 months due to loss of appetite?
Severe loss of appetite 0
Moderate loss of appetite 1
No loss of appetite 2
How much fluids consumed per day?
< 5 glasses 0
5–9 glasses 0.5
> 9 glasses 1
Mode of feeding
With assistance 0
Self-feed with some difficulty 1
Ungar et al. BMC Cardiovascular Disorders  (2018) 18:1 Page 11 of 16
Appendix 3
Illustrates how the Silver Code is calculated.
Table 5 Breakdown of MPI Scoring (Continued)
Self-feed without any problem 2
Self Assessment
Do they view themselves as having nutritional problems?
Major malnutrition 0
Does not know 1
No nutritional problems 2
In comparison with other people of same age, how they consider their health status?
Not as good 0
Does not know 0.5
As good 1
Better 2
Max MNA score (best-nourished) 30
Legend: The numbering on the left-hand side of score titles corresponds to the numbering of factors in Appendix 1
Table 6 Calculation of the Silver Code
Factor Points
Age
75–79 0
80–84 3
85+ 9
Gender
Female 0
Male 2
Marital status
Married 0
Unmarried/widowed/divorced 1
Previous admission to a day hospital
No 0
Yes 5
Previous admission to a regular ward and discharge diagnosis
No admission (0) 0
Respiratory disease (6) 6
Cancer (11) 11
Other (2) 2
Number of drugs in the previous 3 mo
0–8 0
8+ 2
Total score: 0 pts. = best possible performance, 36 pts. = worst possible performance– Corresponds to gradient risk for mortality
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Appendix 4
Describes the components of the Short Physical Performance
Battery (SPPB).
Appendix 5
Details about procedural aspects are provided.
Table 7 Short Physical Performance Battery (SPPB)
Instructions Scoring
1. Repeated Chair Stands
• Ask patient if they think it is safe for them to try and stand up from a chair five times without using their
arms.
• If yes, instruct patient to stand up straight and then sit back down again as quickly as they can five times,
without stopping in between, keeping their arms folded over their chest.
• Demonstrate.
• Begin the stopwatch when patient begins to stand up. Count aloud each time patient rises.
• Stop the stopwatch when subject has straightened up completely for the fifth time. Also stop if the
subject uses arms, if they have not completed rises after 1 min, or if concerned about their safety.
- <5 stands completed in ≤1 min =
0 pts.
- 5 stands in >16.7 s and ≤1 min =
1 pt.
- 5 stands in 16.6–13.7 s = 2 pts.
- 5 stands in 13.6–11.2 s = 3 pts.
- 5 stands in <11.1 s = 4 pts
2. Balance Testing
Semitandem:
• Instruct patient to stand with the side of the heel of one foot touching the big toe of the other foot for
10 s (left/right feet as preferred by patient).
• Demonstrate
• Stand next to patient to help them into a semitandem position, allowing them to hold onto your
arms to establish balance.
• Begin timing when patient has the feet in position.
• If unable to hold the semitandem position for 10 s→ side-by-side.
• If able to hold the semitandem position for 10 s→ tandem.
→ Side-by-side:
As for semitandem but with feet together. Patients may use their arms, bend their knees, or move their
body to maintain balance, but may not move their feet.
→ Tandem:
As for semitandem but with the heel of one foot in-front-of and touching the toes of the other foot.
- Side-by-side: <10 s or unable =
0 pts.
- Side-by-side: ≥10 s; semitandem:
<10 s = 1 pt.
- Semitandem: ≥10 s; tandem:
0–2 s = 2 pts.
- Semitandem: ≥10 s; tandem:
3–9 s = 3 pts.
- Tandem: ≥10 s = 4 pts
3. Eight-foot (2.44 m) walk
• Instruct patient to walk at their usual pace to the other end of course (a distance of 8 ft) and to continue
walking until they pass the end of the tape. If they use a cane or other walking aid outside of their home,
they should use it for the test.
• Press the start button on the stopwatch as the participant begins walking. Walk with the patient.
• Measure the time they take to complete the 8-ft course.
- Unable to complete course =
0 pts.
- Completed course in >5.7 s =
1 pt.
- Completed course in 4.1–6.5 s =
2 pts.
- Completed course in 3.2–4.0 s =
3 pts.
- Completed course in <3.1 s =
4 pts
SPPB score: 0 pts. = worst possible performance, 12 pts. = best performance
Score corresponds to gradient risk for mortality, nursing home admission, and disability
Legend: pt. point, SPPB short physical performance battery
Table 8 Procedural characteristics
n/N (%)
Access route
Transfemoral 55/71 (77.5)
Transapical 9/71 (12.7)
Transaortic 7/71 (9.9)
Type of THV
SAPIEN XT 26/71 (36.6)
SAPIEN 3 40/71 (56.3)
Other 5/71 (7.0)
THV diameter
23 mm 37/70 (52.9)
26 mm 26/70 (37.1)
29 mm 7/70 (10.0)
Second valve used 2/71 (2.8)
Pre-implantation balloon dilatation 63/71 (88.7)
Post-delivery balloon dilatation 9/71 (12.7)
Legend: THV transcatheter heart valve
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Appendix 6
Details about periprocedural outcomes are provided.
Appendix 7
Changes of the CGA over 3 month.
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Table 9 Periprocedural outcomes
Mean ± SD / n/N (%)
Device success (VARC-2)a
Absence of procedural mortality 70/70 (100.0)
Correct positioning of THV 70/70 (100.0)
Intended performance of THV 70/70 (100.0)
Intraoperative complicationsb 12/70 (17.1)
Vascular complications requiring treatmentc 7/70 (10.0)
Access-related complications (dissection, rupture) 4/71 (5.6)
Conversion to open surgery (%) 0/70 (0.0)
Paravalvular regurgitation (%)
None/trace 46/70 (65.7)
Mild 22/70 (31.4)
Moderate 2/70 (2.9)
Severe 0/70 (0.0)
Transvalvular leakage (%)
None/trace 62/70 (88.6)
Mild 8/70 (11.4)
Moderate/severe 0/70 (0.0)
AV peak gradient (mmHg) 20.0 ± 12.4 (n = 31)
AV mean gradient (mmHg) 11.3 ± 7.2 (n = 32)
Legend: THV transcatheter heart valve, AV aortic valve
aValve Academic Research Consortium criteria: absence of procedural
mortality, correct positioning of a single prosthetic heart valve into proper
anatomical position, and intended performance of the prosthetic heart valve
(no prosthesis–patient mismatch) and mean aortic valve gradient
bIncludes access-related complications (8 pts), asystole/arrhythmia (2 pts),
haemorrhagic stroke (1 pt) [one patient no further information available]
cIncludes aneurysm, haematoma, pericardial haematoma/effusion (2 pts),
apical bleeding (1 pt)
Table 10 CGA baseline vs 3 months
Baseline 3 months Intra-individual change
N Mean ± SD N Mean ± SD N Mean ± SD 95% CI p-value
MPI total score 71 0.34 ± 0.11 56 0.30 ± 0.13 56 −0.02 ± 0.12 −0.05, 0.01 0.25
ADL 71 0.05 ± 0.15 60 0.07 ± 0.22 60 0.04 ± 0.25 −0.02, 0.11 0.20
IADL 71 0.16 ± 0.29 60 0.21 ± 0.32 60 0.06 ± 0.32 −0.02, 0.14 0.16
SPMSQ 71 0.01 ± 0.06 57 0.02 ± 0.09 57 0.01 ± 0.12 −0.02, 0.04 0.57
CIRS 71 0.82 ± 0.27 56 0.71 ± 0.38 56 −0.12 ± 0.25 −0.18, −0.05 < 0.001
MNA 71 0.30 ± 0.33 56 0.21 ± 0.28 56 −0.07 ± 0.37 −0.17, 0.03 0.16
ESS 71 0.08 ± 0.22 56 0.02 ± 0.09 56 −0.04 ± 0.13 −0.07, 0.0 0.04
Medication use 71 0.86 ± 0.24 60 0.88 ± 0.21 60 0.04 ± 0.27 −0.03, 0.11 0.23
Co-habitation status 71 0.42 ± 0.50 60 0.31 ± 0.46 60 −0.08 ± 0.39 −0.18, 0.03 0.14
Silver code 71 22.53 ± 6.44 57 22.8 ± 6.33 57 −0.31 ± 3.55 −0.64, 1.25 0.52
SPPB 71 5.69 ± 3.33 56 7.82 ± 2.84 56 1.86 ± 2.76 1.12, 2.60 < 0.001
Legend: MPI Multidimensional Prognostic Index, ADL Activities of Daily Living, Instrumental Activities of Daily Living, SPMSQ Short Portable Mental Status
Questionnaire, CIRS Cumulative Illness Rating Scale, MNA Mini Nutritional Assessment, ESS Exton-Smith Scale, SPPB short physical performance battery
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